| Autor: |
He, Ziyuan, Vadali, VL Gouri, Szabady, Rose L., Zhang, Wenming, Norman, Jason M., Roberts, Bruce, Tibshirani, Robert, Desai, Manisha, Chinthrajah, R. Sharon, Galli, Stephen J., Andorf, Sandra, Nadeau, Kari C. |
| Předmět: |
|
| Zdroj: |
Allergy; Mar2021, Vol. 76 Issue 3, p927-930, 4p |
| Abstrakt: |
In this pilot study, we sought to characterize the gut microbiome from a cohort of peanut-allergic patients who participated in our double-blind, randomized, placebo-controlled, phase 2 peanut OIT study and who successfully desensitized.5 We retrospectively investigated stool samples collected from seven participants who received peanut flour as OIT, sampled before and after 52 weeks of OIT (Table 1). Microbiome, food allergy, OIT, peanut allergy, clinical trial Manipulating the gut microbiota has been proposed as an adjunct to FA immunotherapy to enhance safety and efficacy.3 Oral immunotherapy (OIT) is widely studied in clinical trials, and the PALFORZIA (AR101) OIT regimen is the first FDA-approved treatment for peanut allergy.4 However, whether the gut microbial composition is altered during successful OIT in peanut-allergic patients is unknown. Keywords: microbiome; food allergy; OIT; peanut allergy; clinical trial EN microbiome food allergy OIT peanut allergy clinical trial 927 930 4 03/09/21 20210301 NES 210301 It has been estimated that around 10.8% of adults in the United States suffer from food allergy (FA), and 1.8% of adults are allergic to peanut.1 The striking generational increase of FA prevalence has been associated with changes in the environment, including the gut microbiota.2 The gut microbiota shapes the development of the host immune system, and the host immune system in return influences the microbial composition. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text